Cas no 151377-74-1 (N,N’-Desethylene-N,N’-diformyl Levofloxacin)
N,N’-Desethylene-N,N’-diformyl Levofloxacin Chemical and Physical Properties
Names and Identifiers
-
- N,N'-Desethylene-N,N'-diforMyl Levofloxacin
- (S)-9-Fluoro-10-[forMyl[2-(forMylMethylaMino)ethyl]aMino]-2,3-dihydro-3-Methyl-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic Acid
- N,N’-Desethylene-N,N’-diformyl Levofloxacin
- N,N’-DESETHYLENE-N,N’-DIFORMYL LEVOFLOXACIN,TAN SOLID
- Levofloxacin IMP
- N,N'-Desethylene-N
- Levofloxacin impurity
- (s)-ofloxacin Impurity
- Levofloxacin DiforMyl IMpurity
- Levofloxacin Desethylene DiforMyl IMpurity
- (S)-9-Fluoro-3-methyl-10-(N-(2-(N-methylformamido)ethyl)formamido)-7-oxo-3,7-dihydro-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid
- 7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid, 9-fluoro-10-[formyl[2-(formylmethylamino)ethyl]amino]-2,3-dihydro-3-methyl-7-oxo-, (S)-
- (3S)-9-Fluoro-10-(formyl{2-[formyl(methyl)amino]ethyl}amino)-3-methyl-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid
- (2S)-7-fluoro-6-[formyl-[2-[formyl(methyl)amino]ethyl]amino]-2-methyl-10-oxo-4-oxa-1-azatricyclo[7.3.1.05,13]trideca-5(13),6,8,11-tetraene-11-carboxylic acid
- N26U9LD9HM
- DTXSID60747525
- 151377-74-1
- G87698
- (S)-9-Fluoro-10-[formyl[2-(formylmethylamino)ethyl]amino]-2,3-dihydro-3-methyl-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic Acid; Levofloxacin Desethylene Diformyl Impurity
-
- Inchi： 1S/C18H18FN3O6/c1-10-7-28-17-14-11(16(25)12(18(26)27)6-22(10)14)5-13(19)15(17)21(9-24)4-3-20(2)8-23/h5-6,8-10H,3-4,7H2,1-2H3,(H,26,27)/t10-/m0/s1
- InChI Key： HTOKHJLTWLBPPN-JTQLQIEISA-N
- SMILES： FC1C=C2C(C(C(=O)O)=CN3C2=C(C=1N(C=O)CCN(C=O)C)OC[C@@H]3C)=O
Computed Properties
- Exact Mass: 391.11800
- Monoisotopic Mass: 391.11796346g/mol
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 1
- Hydrogen Bond Acceptor Count: 8
- Heavy Atom Count: 28
- Rotatable Bond Count: 5
- Complexity: 701
- Covalently-Bonded Unit Count: 1
- Defined Atom Stereocenter Count: 1
- Undefined Atom Stereocenter Count : 0
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 0
- XLogP3: 0.8
- Topological Polar Surface Area: 108?2
Experimental Properties
- Melting Point: 179-181°C
- PSA: 109.15000
- LogP: 2.11500
N,N’-Desethylene-N,N’-diformyl Levofloxacin Security Information
- Signal Word：warning
- Hazard Statement： H303May be harmful if swallowed+H313Skin contact may be harmful+H333Inhalation may be harmful to the body
- Warning Statement： P264+P280+P305+P351+P338+P337+P313
- Safety Instruction： H303+H313+H333
- Storage Condition：Store at recommended temperature
N,N’-Desethylene-N,N’-diformyl Levofloxacin Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| TRC | D289330-1mg |
N,N’-Desethylene-N,N’-diformyl Levofloxacin |
151377-74-1 | 1mg |
$150.00 | 2023-05-18 | ||
| TRC | D289330-2mg |
N,N’-Desethylene-N,N’-diformyl Levofloxacin |
151377-74-1 | 2mg |
$193.00 | 2023-05-18 | ||
| TRC | D289330-2.5mg |
N,N’-Desethylene-N,N’-diformyl Levofloxacin |
151377-74-1 | 2.5mg |
$230.00 | 2023-05-18 | ||
| TRC | D289330-5mg |
N,N’-Desethylene-N,N’-diformyl Levofloxacin |
151377-74-1 | 5mg |
$ 431.00 | 2023-09-08 | ||
| TRC | D289330-10mg |
N,N’-Desethylene-N,N’-diformyl Levofloxacin |
151377-74-1 | 10mg |
$ 821.00 | 2023-09-08 | ||
| TRC | D289330-25mg |
N,N’-Desethylene-N,N’-diformyl Levofloxacin |
151377-74-1 | 25mg |
$ 1774.00 | 2023-09-08 |
N,N’-Desethylene-N,N’-diformyl Levofloxacin Related Literature
-
Qiyuan Wu,Shangmin Xiong,Peichuan Shen,Shen Zhao,Alexander Orlov Catal. Sci. Technol., 2015,5, 2059-2064
-
2. Excimer emission and magnetoluminescence of radical-based zinc(ii) complexes doped in host crystals?Shojiro Kimura,Tetsuro Kusamoto Chem. Commun., 2020,56, 11195-11198
-
Peiyuan Zeng,Xiaoxiao Wang,Ming Ye,Qiuyang Ma,Jianwen Li,Wanwan Wang,Baoyou Geng,Zhen Fang RSC Adv., 2016,6, 23074-23084
-
Max Attwood,Hiroki Akutsu,Lee Martin,Toby J. Blundell,Pierre Le Maguere,Scott S. Turner Dalton Trans., 2021,50, 11843-11851
-
Joseph H. Bisesi,Tara Sabo-Attwood Environ. Sci.: Nano, 2014,1, 574-583
Additional information on N,N’-Desethylene-N,N’-diformyl Levofloxacin
Research Brief on N,N’-Desethylene-N,N’-diformyl Levofloxacin (CAS: 151377-74-1)
N,N’-Desethylene-N,N’-diformyl Levofloxacin (CAS: 151377-74-1) is a derivative of levofloxacin, a well-known fluoroquinolone antibiotic. This compound has garnered significant attention in recent years due to its potential applications in enhancing antibacterial efficacy and addressing resistance mechanisms. Recent studies have focused on its synthesis, pharmacokinetics, and biological activity, aiming to explore its therapeutic potential in treating bacterial infections, particularly those resistant to conventional fluoroquinolones.
The synthesis of N,N’-Desethylene-N,N’-diformyl Levofloxacin involves a series of chemical modifications to the parent levofloxacin molecule. Researchers have optimized the reaction conditions to improve yield and purity, which are critical for pharmaceutical applications. Advanced analytical techniques, such as high-performance liquid chromatography (HPLC) and mass spectrometry (MS), have been employed to characterize the compound and ensure its structural integrity. These efforts have laid a solid foundation for further preclinical and clinical evaluations.
In vitro studies have demonstrated that N,N’-Desethylene-N,N’-diformyl Levofloxacin exhibits potent antibacterial activity against a broad spectrum of Gram-positive and Gram-negative bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and multidrug-resistant Pseudomonas aeruginosa. The compound's mechanism of action involves inhibition of bacterial DNA gyrase and topoisomerase IV, similar to other fluoroquinolones, but with enhanced binding affinity and reduced susceptibility to resistance mutations. These findings suggest its potential as a next-generation antibiotic for combating resistant infections.
Pharmacokinetic studies in animal models have revealed favorable absorption and distribution profiles for N,N’-Desethylene-N,N’-diformyl Levofloxacin. The compound shows improved bioavailability compared to levofloxacin, with prolonged half-life and sustained therapeutic concentrations in target tissues. These properties are attributed to its structural modifications, which enhance stability and reduce metabolic degradation. Such pharmacokinetic advantages could translate into reduced dosing frequency and improved patient compliance in clinical settings.
Despite these promising results, challenges remain in the development of N,N’-Desethylene-N,N’-diformyl Levofloxacin. Toxicity studies are ongoing to assess its safety profile, particularly regarding potential adverse effects on the central nervous system and musculoskeletal system, which are known concerns with fluoroquinolones. Additionally, scalable synthesis methods and cost-effective production processes need to be established to facilitate large-scale manufacturing and commercialization.
In conclusion, N,N’-Desethylene-N,N’-diformyl Levofloxacin (CAS: 151377-74-1) represents a promising candidate for addressing the growing threat of antibiotic resistance. Its enhanced antibacterial activity, improved pharmacokinetics, and potential for overcoming resistance mechanisms make it a valuable focus of current research. Continued efforts in preclinical and clinical development will be essential to fully realize its therapeutic potential and bring it to market as a viable treatment option for resistant bacterial infections.
151377-74-1 (N,N’-Desethylene-N,N’-diformyl Levofloxacin) Related Products
- 138199-71-0(Levofloxacin hydrate)
- 100986-86-5((R)-Ofloxacin)
- 104721-52-0(7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylicacid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-4-oxido-1-piperazinyl)-7-oxo-)
- 82419-36-1(Ofloxacin)
- 294662-18-3(Lavofloxacin Lactate)
- 1217716-71-6(Levofloxacin-d)
- 100986-85-4(Levofloxacin)
- 83380-47-6(OFLOXACIN)
- 177472-30-9(Levofloxacin Ethyl Ester)
- 117707-40-1(Desmethyl levofloxacin)
Audited Supplier
Audited Supplier
Audited Supplier
Audited Supplier
Audited Supplier
